Drug Type TCR-T Cell therapy |
Synonyms TCRTESOA2, TCRTESOA2Axis Therapeutics |
Target- |
Action- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Head and Neck Neoplasms | Phase 1 | China | 06 Nov 2021 | |
| Hepatocellular Carcinoma | Phase 1 | China | 06 Nov 2021 | |
| Lung Cancer | Phase 1 | China | 06 Nov 2021 | |
| Sarcoma | Phase 1 | China | 06 Nov 2021 | |
| Squamous Cell Carcinoma | Phase 1 | China | 06 Nov 2021 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 11 Aug 2021 | |
| Solid tumor | Preclinical | United States | - | |
| Solid tumor | Preclinical | United States | - | |
| Solid tumor | Preclinical | United States | - | |
| Solid tumor | Preclinical | China | - |





